文献速递妇科

血清5-羟甲基胞嘧啶信号预测高级别浆液性卵巢癌化疗耐药

5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-01-22

本研究从存档血清cfDNA中检测5hmC信号,建立由术前CA-125、术后最大残留病灶和OSGEPL1的5hmC水平组成的多变量模型,可将中间敏感、初治HGSOC患者分为化疗耐药样和敏感样两层,总生存差异显著;作者认为需在更大队列中进一步验证模型的预测能力。

要点

  • 基于cfDNA的5hmC特征联合临床病理指标建立多变量模型,可对中间敏感HGSOC分层。
  • 模型包含术前CA-125、术后最大残留病灶和OSGEPL1的5hmC水平三个特征。
  • 作者认为该模型在更大队列中的预测能力需进一步研究。

核心结论

  • 作者建立了基于临床病理数据和cfDNA来源的5hmC修饰基因OSGEPL1的多变量模型,可预测中间敏感HGSOC对铂类化疗的反应。
  • 该多变量模型适用于初治样本,无论患者接受辅助还是新辅助化疗。
  • 作者认为这些结果值得在更大队列中进一步研究该模型的预测能力。

研究设计与样本

  • 研究纳入确诊HGSOC且已知铂敏感状态的女性,从存档血清样本中分离cfDNA进行Nano-hmC-Seal检测。
  • 使用DESeq2识别差异5hmC特征,建立预测化疗耐药的模型。
  • 独立分析癌症基因组图谱(The Cancer Genome Atlas)数据以验证OSGEPL1表达的预后意义。

主要发现

  • 由术前CA-125、术后最大残留病灶和OSGEPL1的5hmC水平三个特征组成的多变量模型,将中间敏感、初治HGSOC样本分为化疗耐药样和敏感样两层,两层总生存差异显著。
  • 对癌症基因组图谱数据的独立分析进一步证实,OSGEPL1高表达是HGSOC的有利预后因素。

局限性

  • 作者指出这些结果值得在更大队列中进一步研究该模型的预测能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The genome-wide profiling of 5-hydroxymethylcytosines (5hmC) on circulating cell-free DNA (cfDNA) has revealed promising biomarkers for various diseases. The purpose of this study was to investigate 5hmC signals in serum cfDNA and identify novel predictive biomarkers for the development of chemoresistance in high-grade serous ovarian cancer (HGSOC). We hypothesized that 5hmC profiles in cfDNA reflect the development of chemoresistance and elucidate pathways that may drive chemoresistance in HGSOC. Moreover, we sought to identify predictors that would better stratify outcomes for women with intermediate-sensitive HGSOC. METHODS: Women diagnosed with HGSOC and known platinum sensitivity status were selected for this study. Nano-hmC-Seal was performed on cfDNA isolated from archived serum samples, and differential 5hmC features were identified using DESeq2 to establish a model predictive of chemoresistance. RESULTS: A multivariate model consisting of three features (preoperative CA-125, largest residual implant after surgery, 5hmC level of OSGEPL), stratified samples from intermediate sensitive, chemo-naive women diagnosed with HGSOC into chemotherapy-resistant- and sensitive-like strata with a significant difference in overall survival (OS). Independent analysis of The Cancer Genome Atlas data further confirmed that high OSGEPL1 expression is a favorable prognostic factor for HGSOC. CONCLUSIONS: We have developed a novel multivariate model based on clinico-pathologic data and a cfDNA-derived 5hmC modified gene, OSGEPL1, that predicted response to platinum-based chemotherapy in intermediate-sensitive HGSOC. Our multivariate model applies to chemo-naïve samples regardless if the patint was treated with adjuvant or neoadjuvant chemotherapy. These results merit further investigation of the predictive capability of our model in larger cohorts.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Weigert M, Cui XL, West-Szymanski D, et al. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Gynecol Oncol. 2024. PMID: 38262243. doi:10.1016/j.ygyno.2024.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。